Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
276
NCT01935154
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 31, 2012
Completion: Jan 31, 2017
NCT02289196
Safety Study of Vx006 Vaccine in Solid Tumor Patients
Phase: Phase 1
Start: Mar 31, 2014
Completion: May 31, 2017
NCT04455503
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
Phase: Phase 1/2
Start: Jul 13, 2020
Completion: Mar 28, 2023
NCT05309421
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Start: Sep 19, 2022
Completion: Mar 30, 2026